Cartesian Therapeutics, Inc.
RNAC- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001453687
No open-market purchases or sales by Cartesian Therapeutics, Inc. insiders were filed in the last 90 days; 99 institutions reported holding it in 13F filings for Q3 2026, worth $63.0M in total; no superinvestor holds it.
Key figures
- Market capClose on Nov 20, 2026
- $187.3M
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ3 2026, +7 vs. previous quarter
- 99
- 13F valueReported value at the end of Q3 2026
- $63.0M
- Superinvestors holdingAt the end of Q3 2026
- 0
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2025
- $2.80M
- −92.8% year over year
- Net income, FY2025
- -$130.3M
- No comparable prior period
- Free cash flow, FY2025
- -$79.4M
- No comparable prior period
- Revenue, Q3 FY2026
- $0
- −100.0% year over year
Revenue flow, FY2025
Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.
Net loss for FY2025: $130.3M (4658.6% of revenue).
Short interest
See short dataFrom FINRA, settlement date Oct 30, 2026.
- Short interest
- 1.92M
- Shares sold short
- Change
- +41.2K
- +2.2% vs. previous
- Days to cover
- 16.50
- At average daily volume
Superinvestors holding RNAC, Q3 2026
Go to the superinvestors tabNo superinvestor reported holding RNAC at the end of Q3 2026.
Latest insider trades
See all insider tradesOpen-market purchases and sales by Cartesian Therapeutics, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jan 8, 2026 (view filing) | Jan 6 | 2 days | Brunn CarstenPresident and CEO | SSale | −23.8K | $6.82 | −$162.1K | −6.8%323.5K after | |
| Jan 8, 2026 (view filing) | Jan 6 | 2 days | Miljkovic MilosChief Medical Officer | SSale | −3.57K | $6.82 | −$24.4K | −5.7%58.8K after | |
| Jan 8, 2026 (view filing) | Jan 6 | 2 days | Davis BlaineChief Financial Officer | SSale | −10.6K | $6.82 | −$72.2K | −8.0%121.2K after | |
| Dec 8, 2025 (view filing) | Dec 4 | 4 days | Barabe Timothy CDirector | PPurchase | +30.0K | $6.86 | +$205.8K | +123.1%54.4K after | |
| Apr 11, 2025 (view filing) | Apr 9-11 | 2 days | Springer Timothy ADirector, 10% Owner | PPurchase | +22.4K | $10.21 | +$228.3K | +0.3%8.64M after | 5 lots |
| Apr 11, 2025 (view filing) | Apr 9-11 | 2 days | Springer Timothy ADirector, 10% Owner | PPurchase | +126.7K | $10.21 | +$1.29M | +23.9%656.5K after | 5 lots |
| Mar 20, 2025 (view filing) | Mar 18-20 | 2 days | Springer Timothy ADirector, 10% Owner | PPurchase | +89.9K | $15.26 | +$1.37M | +1.1%8.62M after | 3 lots |
| Jan 15, 2025 (view filing) | Jan 13-14 | 2 days | Springer Timothy ADirector, 10% Owner | PPurchase | +21.0K | $17.47 | +$366.4K | +0.2%8.53M after | 3 lots |
| Jan 7, 2025 (view filing) | Jan 3-6 | 4 days | Kurtoglu MetinChief Technology Officer | SSale | −4.88K | $16.78 | −$81.8K | −7.3%62.3K after | 2 lots |
| Jan 7, 2025 (view filing) | Jan 3-6 | 4 days | Miljkovic MilosChief Medical Officer | SSale | −1.88K | $16.78 | −$31.5K | −5.0%35.4K after | 2 lots |
Top 10 13F holders, Q3 2026
See all 99 holdersThe largest institutional positions in Cartesian Therapeutics, Inc. at the end of Q3 2026; share changes are against Q2 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Squarepoint Ops LLC | 2,263,230 | $16.3M | 0.03% | +8,611+0.4% | Added |
| BlackRock, Inc. | 808,458 | $5.83M | 0.00% | −10,781−1.3% | Reduced |
| 683 Capital Management, LLC | 751,000 | $5.41M | 0.52% | +101,000+15.5% | Added |
| Vanguard Capital Management LLC | 555,823 | $4.01M | 0.00% | 00.0% | Unchanged |
| FMR LLC | 370,457 | $2.67M | 0.00% | +2,028+0.6% | Added |
| Two Sigma Investments, LP | 367,350 | $2.65M | 0.00% | +71,057+24.0% | Added |
| Geode Capital Management, LLC | 342,829 | $2.47M | 0.00% | −13,696−3.8% | Reduced |
| AQR Capital Management LLC | 287,156 | $2.07M | 0.00% | −69,300−19.4% | Reduced |
| State Street Corp | 261,736 | $1.89M | 0.00% | +12,524+5.0% | Added |
| Marshall Wace, LLP | 243,545 | $1.76M | 0.00% | +10,626+4.6% | Added |
Holders of 5% or more of RNAC
See all 3 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of Cartesian Therapeutics, Inc..
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Springer Timothy A | 13D/A | 36.90%9.56M shares | +0.10 ppfrom 36.80% | May 27, 202113 filings | Jan 15, 2025 | SEC |
| Kalayoglu Murat | 13D/A | 19.90%5.83M shares | – | Nov 22, 20234 filings | Apr 2, 2026 | SEC |
| Squarepoint Ops LLC | 13G | 8.30%2.21M shares | New | Mar 13, 20261 filing | Mar 13, 2026 | SEC |